Panobinostat - CAS 404950-80-7
Catalog number: B0084-141578
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-141578 500 mg $298 In stock
Bulk Inquiry
Light yellow to yellow Solid
LBH589; LBH 589; LBH-589; NVP-LBH589; NVP-LBH 589; Panobinostat; trade name Farydak
Canonical SMILES:
Current Developer:
Novartis Oncology.
1.Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K1, Beggs AE2, Campbell H2, Kodali L2, Ford PD3. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487.
PURPOSE: The mechanism of action, pharmacodynamics, pharmacokinetics, clinical efficacy, interaction potential, adverse effects, and place in therapy of panobinostat are reviewed.
2.Dinutuximab and Panobinostat.
Chasick A1, Solimando DA Jr1, Waddell JA1. Hosp Pharm. 2015 Oct;50(9):767-72. doi: 10.1310/hpj5009-767. Epub 2015 Oct 14.
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail:; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail:
3.Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine.
Gupta S1, Chaudhary K1, Kumar R1, Gautam A1, Nanda JS1, Dhanda SK1, Brahmachari SK2, Raghava GP1. Sci Rep. 2016 Mar 31;6:23857. doi: 10.1038/srep23857.
In this study, we investigated drug profile of 24 anticancer drugs tested against a large number of cell lines in order to understand the relation between drug resistance and altered genomic features of a cancer cell line. We detected frequent mutations, high expression and high copy number variations of certain genes in both drug resistant cell lines and sensitive cell lines. It was observed that a few drugs, like Panobinostat, are effective against almost all types of cell lines, whereas certain drugs are effective against only a limited type of cell lines. Tissue-specific preference of drugs was also seen where a drug is more effective against cell lines belonging to a specific tissue. Genomic features based models have been developed for each anticancer drug and achieved average correlation between predicted and actual growth inhibition of cell lines in the range of 0.43 to 0.78. We hope, our study will throw light in the field of personalized medicine, particularly in designing patient-specific anticancer drugs.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HDAC Products

CAS 875320-31-3 JNJ 26481585 dihydrochloride

JNJ 26481585 dihydrochloride
(CAS: 875320-31-3)

JNJ 26481585 dihydrochloride is a potent and second-generation pan-HDAC inhibitor (IC50 value 0.11 nM for HDAC1, and sub-nanomolar for HDAC2, HDAC4, HDAC10, and...

CAS 99873-43-5 Droxinostat

(CAS: 99873-43-5)

Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respec...

CAS 497833-27-9 Givinostat

(CAS: 497833-27-9)

Givinostat (INN) or gavinostat, aslo known as ITF2357,  is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic...

CAS 1622921-15-6 Remodelin

(CAS: 1622921-15-6)

Remodelin, via inhibition of NAT10, mediates nuclear shape rescue of LMNA depleted cells by microtubule reorganization, and improves nuclear shape and fitness o...

CAS 151720-43-3 Oxamflatin

(CAS: 151720-43-3)

Oxamflatin, also known as Metacept-3, an aromatic sulfonamide derivative, is a cell-permeable, potent HDAC inhibitor (IC50= 15.7 nM) with antitumor effect.

CAS 929016-96-6 Pracinostat

(CAS: 929016-96-6)

Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits ...

CAS 726169-73-9 Mocetinostat

(CAS: 726169-73-9)

Mocetinostat is a rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activi...

CAS 1069-66-5 Valproic acid sodium salt (Sodium valproate)

Valproic acid sodium salt (Sodium valpro
(CAS: 1069-66-5)

Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention o...

Chemical Structure

CAS 404950-80-7 Panobinostat

Quick Inquiry

Verification code

Featured Items